Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects
Subjects were aged 15-55 years at the time of entry into the primary study (NCT00196937). No
vaccine will be administered in this extension study.
Results on outcome measures describing analyses on other studies are not reported in this
record. Please refer to the records mentioned in the respective outcome measure titles.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum
Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL).
At Year 5 and 6
GSK Clinical Trials